|
MechanismPSMB5 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismProteasome inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with QLi5 Therapeutics GmbH
0 Patents (Medical) associated with QLi5 Therapeutics GmbH
100 Deals associated with QLi5 Therapeutics GmbH
100 Translational Medicine associated with QLi5 Therapeutics GmbH